To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward looking and are often identified by
words such as "anticipate ," "expect," "estimate," "intend," "project," "plan"
and "believe.

ITAX is a trademark of Axcan or its affiliates. Gosselin.

The names ITAX, Salofalk, Helizide, Hepenax, Photofrin and Canasa
appearing in this press release are trademarks of Axcan Pharma Inc.

bowel conditions

TSX Symbol (Toronto Stock Exchange): AXP
NASDAQ Symbol (NASDAQ National Market): AXCA

MONT SAINT -HILAIRE, QC, June 9 - Axcan Pharma Inc.

inflammatory born

axcan.
Axcan's products are marketed by its own sales force in North America and
Europe.
("Axcan" or the "Company") announced today that it has enrolled more than 1000
patients in the Company's two Phase III studies on ITAX (Itopride
hydrochloride) for the treatment of functional dyspepsia.

support ostomies

bowel vater

More than 1000 patients enrolled in Axcan's ITAX Phase III functional dyspepsia studies

disease vater

To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward looking and are often identified by
words such as "anticipate," "expect," "estimate," "intend," "project," "plan"
and "believe. Gosselin pointed out that ITAX alone could "more than double" Axcan's
revenues.

heartburn inflammatory

com.

liver disease

Other regulatory filings in Canada and
selected Western European countries will follow in the second quarter of 2006.

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995. "That is why we believe that a
substantial increase in our research and development budget for fiscal 2005 is
necessary to take full advantage of the multiple new product launch
opportunities that the future holds for Axcan, including ITAX, which could be
the biggest product in Axcan's history. Axcan markets a broad line of prescription products sold
for the treatment of symptoms in a number of gastrointestinal diseases and
disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Actual results could differ
materially from those projected herein and depend on a number of factors,
including, but not limited to, the successful and timely completion of
clinical studies, the difficulty of predicting FDA and other regulatory
approvals, the commercialization of a drug or therapy after regulatory
approval is received , acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, new product
development and launch, reliance on key strategic alliances, availability
of raw materials, the regulatory environment, fluctuations in our
operating results, the protection of our intellectual property and other
risks detailed from time to time in the Company 's filings with the
Securities and Exchange Commission and under the Canadian Securities
Commissions.

heartburn vater

Axcan expects to complete its Functional Dyspepsia Phase III
program in the fourth quarter of 2005.

Annual General Meeting of Shareholders - Axcan Prepares for a New Era of Growth - Advances ITAX Development Program and Launch Strategy

"Beyond the year 2007, I strongly believe that Axcan will be able to
launch innovative products at an average rate of one per year for each of the
following five years," said Mr.

atresia disease

Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events.

inflammatory health

Axcan Pharma to present at Merrill Lynch Global Healthcare Conference

Recruitment
activities will continue for a few weeks." Forward-looking statements are subject to risks and
uncertainties , including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results , the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
securities regulatory authorities. 17 - During the
Axcan Pharma Inc .
Gosselin, announced a new era of growth for Axcan citing as key factors, the
expansion of the Company's product pipeline during the last five years,
including the potential "blockbuster" drug , ITAX (itopride hydrochloride) for
the treatment of functional dyspepsia, and a 9% to 11% increase in the fiscal
2005 research and development budget.

esophageal atresia

The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.

ABOUT FUNCTIONAL DYSPEPSIA

Functional dyspepsia, a disorder of the upper gastrointestinal system,
affects up to 25% of the US population annually and accounts for up to 5% of
all visits to primary care physicians in the USA (Talley et al
Gastroenterology 1992:102;1259-1268).
Assuming continued positive results of clinical trials and regulatory
approval , Axcan's product candidates approaching commercialization are:

<<
--------------- ----------------------------------------------------------
Product Candidate Indication Estimated Launch Date
------------------------------------------------------------ -------------
HELIZIDE Eradication of - Second half, fiscal 2006
Helicobacter
pylori bacterium
------------- ------------------------------------------------------------
CANASA (rectal gel) Treatment of Distal - Second half, fiscal 2006
Ulcerative Colitis
------- ------------------------------------------------------------------
ITAX Treatment of - First half, fiscal 2007
Functional Dyspepsia

Treatment of - Fiscal 2008
Diabetic Gastroparesis
-------------------------------------------------------------------------
HEPENAX Treatment of - Second half, fiscal 2008
Porto-Systemic
Encephalopathy
------------------------------------------------- ------------------------
PHOTOFRIN Treatment of - Phase III to start during
Cholangiocarcinoma second quarter 2005

- Launch date to be
determined
-------------------------------------------------------------------------
>>

ABOUT AXCAN PHARMA

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology.

diseases hirschsprungs

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995. Currently, there are no known approved
drugs for this indication in the United States. The Company markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease , irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis . To the extent any
statements made in this release contain information that is not
historical , these statements are essentially forward looking and are
often identified by words such as "anticipate," "expect," "estimate,"
"intend," "project," "plan" and "believe. The Company disclaims any obligation to update these
forward-looking statements.

fistula tef

31 - Axcan Pharma
Inc. Its common shares are listed on the Toronto Stock Exchange
under the symbol "AXP" and on the NASDAQ National Market under the symbol
"AXCA"."
Mr.

born esophageal

The Company has also enrolled more
than 300 patients who will receive active medication for six months in
accordance with the International Conference on Harmonisation ("ICH")
guidelines."
ITAX is a patented oral gastroprokinetic drug containing itopride
hydrochloride, which increases upper gastrointestinal motility and possesses
antiemetic properties.

digestive esophageal

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. Total revenues for the Company in fiscal
2004 were $243.

groups source

D., will
present an overview of the Company at Merrill Lynch's Global Pharmaceutical ,
Biotechnology and Medical Device Conference held in New York, NY. In addition to functional dyspepsia Axcan plans to
investigate the use of ITAX for the treatment of diabetic gastroparesis +
gastropathy .

digestive diseases

" Forward-looking statements are subject to risks and
uncertainties, including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products , the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results, the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
securities regulatory authorities.7 million (all dollar amounts
stated in US dollars). Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

born inflammatory

TSX SYMBOL (Toronto Stock Exchange): AXP
NASDAQ SYMBOL (NASDAQ National Market): AXCA

MONT SAINT-HILAIRE, QC, Jan. ("Axcan" or the "Company") today announced that on Tuesday, February 7,
2006, president and chief executive officer, Frank A.
Apart from the Company's present portfolio and pipeline of products,
shareholders also learned that Axcan is well positioned to pursue strategic,
accretive acquisitions with $70 million in annual cash flow, $40 million in
cash and cash equivalents and a $125-million unused credit facility.

atresia irritable

The Company has built a strong multi-product gastrointestinal base
focusing on unmet therapeutic needs.

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995.

esophageal liver

G. Work has begun on preparing the ITAX
New Drug Application ("NDA") to be filed during the first half of 2006, most
likely at the end of the first quarter. ("Axcan" or the "Company") annual shareholders' meeting held
today in Montreal, President and Chief Executive Officer, Mr. Leon F." Forward-looking statements are
subject to risks and uncertainties.

liver conditions

"The approval and launch of ITAX,
expected in early calendar 2007, will allow Frank Verwiel and the Axcan team
to take the Company to the next level .

heartburn fistula

M.
A webcast of Axcan's presentation can also be accessed via the Company's
website at http: //www. Axcan's core business, always geared
towards gastroenterology, revolves around five therapeutic areas: diseases of
the liver, the pancreas, the bowel, gastrointestinal (GI) and GI-related
cancers and other gastrointestinal disorders.

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. and
its subsidiaries .

source diseases

Verwiel, M. This
presentation will take place at 10:20 A.

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology.
"We are very pleased to have reached this important milestone in our ITAX
development program," said Leon F. Gosselin, Chairman and outgoing President
and Chief Executive Officer of Axcan.
Axcan's products are marketed by its own sales force in North America and
Western Europe.6 million with net income of $48.

irritable conditions

ET.

ABOUT AXCAN PHARMA

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. TSX SYMBOL (Toronto Stock Exchange): AXP
NASDAQ SYMBOL (NASDAQ National Market): AXCA

MONT-SAINT-HILAIRE, Quebec, Feb. The reader is cautioned not to rely on these
forward-looking statements.